scholarly journals Clinical review: Acute respiratory distress syndrome - clinical ventilator management and adjunct therapy

Critical Care ◽  
2013 ◽  
Vol 17 (2) ◽  
pp. 225 ◽  
Author(s):  
Jonathan A Silversides ◽  
Niall D Ferguson
2020 ◽  
Vol 17 (9) ◽  
pp. 1161-1163 ◽  
Author(s):  
Lieuwe D. J. Bos ◽  
Frederique Paulus ◽  
Alexander P. J. Vlaar ◽  
Ludo F. M. Beenen ◽  
Marcus J. Schultz

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Naoki Kawakami ◽  
Ho Namkoong ◽  
Takanori Ohata ◽  
Shinji Sakaguchi ◽  
Fumitake Saito ◽  
...  

Introduction. The prognosis of mycoplasma pneumonia in adults is generally favorable, but a few patients show progression to acute respiratory distress syndrome (ARDS). We have described the management of a patient who showed progression of mycoplasma pneumonia to ARDS. Presentation of Case. A 26-year-old male patient with no significant past medical or social history presented with a 5-day history of fever. Following this, he was diagnosed with bacterial pneumonia and treated with tazobactam/piperacillin; however, he showed little clinical improvement with this treatment approach. We diagnosed the patient with mycoplasma pneumonia with an antigen test and treated him with azithromycin and prednisolone. Despite the appropriate antimicrobial therapy, his symptoms worsened and therefore we changed his oxygen therapy from a reservoir mask to nasal high-flow oxygen in addition to minocycline. Consequently, with this treatment, he recovered from severe mycoplasma pneumonia. Discussion. In patients with severe pneumonia who experience respiratory failure, it has been reported that nasal high-flow oxygen therapy is not inferior to noninvasive positive pressure ventilation therapy regarding intubation rate. In this case, induction of nasal high-flow oxygen therapy led to avoidance of ventilator management. This is a valuable case report highlighting the optimal outcome of nasal high-flow oxygen therapy in a fulminant case of acute respiratory distress syndrome. Conclusion. In patients who present with severe mycoplasma pneumonia with respiratory failure, nasal high-flow oxygen therapy can help reduce the needs for ventilator management including intubation.


2021 ◽  
Author(s):  
Satriyo Dwi Suryantoro ◽  
Anna Surgean Veterini ◽  
Bagus Aulia Mahdi

Abstract Rebamipide has a noteworthy potential as an adjunct therapy of coronavirus disease (COVID-19) which may act as an anti- IL8. There have been no yet previous studies declared worldwide examining the use of it. We conducted a study of Rebamipide through the secondary data obtained from the medical record then analyzed the neutrophile, lymphocytes, and neutrophil-lymphocyte ratio of patients. Our data exhibited improvements in the laboratory outcomes, revealing decreased neutrophils, increased lymphocytes, also increased neutrophil-lymphocyte rations, observed in COVID-19 patients experiencing acute respiratory distress syndrome (ARDS).


Sign in / Sign up

Export Citation Format

Share Document